



## Pioneers in the New Era of Psychedelic Medicine

Psychedelics have been used as medicine for thousands of years.

Yet research into their potential has long been restricted—until now.

An explosion in new studies and research has proven the incredible therapeutic potential of psychedelic compounds like psilocybin, which could change the face of medicine as we know it.

### More Than Mental Health

Most companies in the psychedelics space are working toward solutions for **debilitating mental health conditions**, such as:

- + PTSD
- + ANXIETY
- + ADDICTION
- + DEPRESSION

But psychedelic medicine has a much larger role to play, particularly when it comes to solving **unmet medical needs**, like:

- + NEUROPSYCHIATRIC DISEASES
- + CHRONIC PAIN
- + RARE DISEASES
- + EATING DISORDERS

As a result, the medicinal psychedelics market could grow significantly by 2027.

Beyond that, experts predict it could eventually become a \$100 billion market.

\$2B  
2019

\$6.8B  
F 2027

Source: Canaccord Genuity Capital Markets

Source: Data Bridge Market Research

Due to challenges such as lack of funding and innovation, there is a range of rare and difficult to treat diseases that urgently require more effective treatment options.

These **unmet medical needs** significantly impact the lives of millions of people, so finding new solutions is critical.

One company is spearheading the movement by harnessing the power of psilocybin.

MEET



Derived from the word *tryptamine*, a natural compound found in all psychedelics.

Tryp Therapeutics is a San Diego-based pharmaceutical company focused on developing psychedelic compounds targeting diseases with high unmet medical needs utilizing proprietary formulations.

In particular, psilocybin has shown advantages over many of the current drugs used on the market, such as:

- Increased efficacy
- Natural blood-brain barrier penetration
- Enhanced safety and toxicity profiles
- Reduced risk of abuse and addiction

Psilocybin is a psychedelic chemical produced by more than 100 species of mushrooms.




## HOW DOES PSILOCYBIN WORK?

Psilocin, which is produced by the body's enzymatic cleavage of psilocybin, interacts with serotonin receptors in the central nervous system. These receptors are involved in pain processes and the regulation of mood, anxiety, and cognition.

Once the compound binds to the receptors, they produce a range of consciousness-altering effects.

### Psilocin bound to Serotonin (5-HT2A) Receptor



Once the compound binds to the serotonin receptors in the brain, they produce a range of consciousness-altering effects.

- Psilocybin has been studied extensively in humans.
- Recently, the FDA designated the substance as a **breakthrough therapy** for certain disorders like treatment-resistant depression and major depressive disorder.

*"We follow the science, and we believe in the strong medical potential of psilocybin."*

—Greg McKee  
CEO of Tryp Therapeutics

There are two programs currently in development using Tryp Therapeutics' proprietary formulations:

Tryp Therapeutics intends to directly enter Phase 2A human clinical trials based on numerous past studies and the safety profile of its formulations.

PROGRAM	INDICATION	EVALUATION	PHASE 1	PHASE 2A & 2B	PHASE 3
PFN™ TRP-8802	BINGE EATING/HYPOTHALAMIC OBESITY				
	FIBROMYALGIA				
	PHANTOM LIMB PAIN				
	COMPLEX REGIONAL PAIN SYNDROME				
PFN™ TRP-8803	PROPRIETARY FORMULATION/DELIVERY				

The proprietary formulation with a novel method of administration, TRP-8803, will be used for Phase 2B and Phase 3 clinical trials.

### Psilocybin-for-Neuropsychiatric Disorders

## PFN™ PROGRAM

Focuses on developing psilocybin-based drug therapies for certain neuropsychiatric disorders.

- CHRONIC PAIN**
  - Fibromyalgia
  - Phantom limb pain
  - Complex regional pain syndrome
  - Others
- EATING DISORDERS**
  - Binge eating disorder
  - Hypothalamic obesity
  - Others

Main disease target for chronic pain

## FIBROMYALGIA

### What is it?

A chronic pain syndrome, characterized by abnormalities in pain processing by the central nervous system. Affecting millions of Americans, and up to 400M people globally.

Source: European Network of Fibromyalgia Associations (ENFA)

### Market forecast:

Expected to grow significantly in the coming years.

The problem is, many existing therapies for fibromyalgia have limited efficacy and significant side effects with **less than 10% of patients adhering to treatment after one year.**

**\$2.7B**  
2018

**\$3.6B**  
F 2026

Source: Coherent Market Insights

**30%** of fibromyalgia patients take chronic opioids, despite the risk of addiction and overdose.

## WHY INVEST IN TRYP THERAPEUTICS?

Tryp Therapeutics is an early leader in the psychedelic medicine space with a differentiated value proposition.

- Unique growth platform
- Diversified pipeline of product candidates
- Established and growing IP portfolio
- Undervalued compared to competitors

### Market Cap




World class management team with extensive experience with developing and commercializing pharmaceutical compounds



Gregory M. McKee  
Executive Chairman and CEO



Jim Gilligan, Ph.D.  
President and CSO



Luke Hayes  
CFO



Robin Carhart-Harris, Ph.D.  
Chairman,  
Scientific Advisory Board



Daniel Clauw, M.D.  
Scientific Advisor




Joel Castellanos, M.D.  
Scientific Advisor

### CAPITAL MARKETS




### BIG PHARMA



### DRUG APPROVALS



### PROFITABLE MEDICAL COMPANIES



### At the Forefront of the Psychedelic Renaissance

Although the psychedelic medical market is in its early days, it has huge potential to transform healthcare.

**Tryp Therapeutics is leading this transformation**, leveraging the proven properties of psilocybin and creating new solutions for diseases without effective first-line treatments.



Promising Relief for Unmet Medical Needs.  
CSE: TRYP  
www.trypterapeutics.com